The results of the study, which were highlighted by Alex Berenson on his Unreported Truths Substack, Daniel Horowitz at the Blaze, and Igor Chudov on his Substack newsletter, completely destroy the regime narrative that the shots provide stronger immunity than a natural infection, and may help explain why so many vaccinated Americans are now suffering from multiple COVID infections.
The pre-print paper was quietly posted by scientists from the National Institutes of Health and Moderna, and as Berenson noted, “it has received little attention despite its import.”
The study analyzed data from the Moderna Phase 3 vaccine trial comparing a vaccinated group with “breakthrough infections” to a control group of unvaccinated people with COVID.
Researchers wanted to find out if the vaccinated group acquired the same full-spectrum immunity as the unvaccinated. The answer was a resounding no.
“We analyzed data from 1,789 participants (1,298 placebo recipients and 491 vaccine recipients) with SARS-CoV-2 infection during the blinded phase (through March 2021). Among participants with PCR-confirmed Covid-19 illness, seroconversion to anti-N Abs at a median follow up of 53 days post diagnosis occurred in 21/52 (40%) of the mRNA-1273 vaccine recipients vs. 605/648 (93%) of the placebo recipients (p < 0.001).”
“Researchers already knew that many vaccinated people do not gain antibodies to the entire coronavirus after they are infected with Covid, Berenson noted.
Unvaccinated people nearly always gain antibodies to the nucleocapsid protein, which covers the virus’s core of RNA, as well as its spike protein, which allows the virus to attack our cells. Vaccinated people often lack those anti-nucleocapsid antibodies and only have spike protein antibodies.The study “all-but-proves” that the mRNA shots “are impeding the development of the anti-nucleocapsid antibodies,” Berenson reported. Because the coronavirus’s spike protein mutates rapidly, antibodies against it are eventually rendered useless. As Berenson noted, “Omicron’s spike is markedly different than that of earlier variants. The nucleocapsid protein mutates far more slowly, offering a potential second line of defense.”
The researchers examined the development of anti-nucleocapsid antibodies in people who had been part of Moderna’s clinical trial and were infected with Covid. As they expected, the scientists found that the vaccinated people were far less likely to develop the anti-nucleocapsid antibodies. Only 40 percent of people who received the shots had antibodies, compared to 93 percent of...